Glaucoma – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23001IDB-L5

Select Item

Empower your strategies with our Glaucoma – Drugs In Development, 2024 report and make more profitable business decisions.

Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow to the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, and family history of glaucoma. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance (often in low light), blurred vision, and reddening of the eye.

The Glaucoma drugs in development market research report provide comprehensive information on the therapeutics under development for Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glaucoma and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Glaucoma
Key Targets
· Prostaglandin F2 Alpha Receptor; Beta 1 Adrenergic Receptor; Beta 2 Adrenergic Receptor; Rho Kinase; Cannabinoid Receptor 2; Cannabinoid Receptor 1; Alpha 2 Adrenergic Receptor; cGMP Specific 3',5' Cyclic Phosphodiesterase; Soluble Guanylate Cyclase; and Prostaglandin (Prostanoid) Receptor
Key Mechanisms of Action
· Prostaglandin F2 Alpha Receptor Agonist; Beta 1 Adrenergic Receptor Antagonist; Beta 2 Adrenergic Receptor Antagonist; Rho Kinase Inhibitor; Cannabinoid Receptor 2 Agonist; Cannabinoid Receptor 1 Agonist; Alpha 2 Adrenergic Receptor Agonist; cGMP Specific 3',5' Cyclic Phosphodiesterase Inhibitor; Soluble Guanylate Cyclase Activator; and Prostaglandin (Prostanoid) Receptor Agonist
Key Routes of Administration
· Ophthalmic; Intraocular; Intravitreal; Oral; Topical; Intravenous; Parenteral; Inhalational; Subcutaneous; and Nasal
Key Molecule Types
· Small Molecule; Gene Therapy; Recombinant Protein; Synthetic Peptide; Antisense RNAi Oligonucleotide; Monoclonal Antibody; Biologic; Cell Therapy; Fusion Protein; and Antisense Oligonucleotide
Major Companies
· Santen Pharmaceutical Co Ltd; NicOx SA; TearClear Corp (Inactive); Sustained Nano Systems LLC; Optus Pharmaceutical Co Ltd; Qlaris Bio Inc; Laboratoires Thea SA; Glaukos Corp; Astellas Pharma Inc; and CalciMedica Inc

Scope

  • Therapeutics in Development: Covering 215 molecules, with 194 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Glaucoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Glaucoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Glaucoma treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

4B Technologies (Suzhou) Co Ltd
AbbVie Inc
AC Immune SA
Adtech Pharma Inc
Advanced Vision Technologies (New York)
AffaMed Therapeutics US Inc
Agency for Science
Technology and Research
Annexon Inc
Arctic Vision Shanghai Biotechnology Co Ltd
Asha Therapeutics LLC
Astellas Pharma Inc
Austin Biosciences Corp
Avirmax Inc
AXONIS Therapeutics Inc
Berlin Cures Holding AG
Betaliq Inc
Biorchestra Co Ltd
Biozeus Pharmaceutical SA
BrainEver SAS
Broadwing Bio
BSIM Therapeutics SA
CalciMedica Inc
Calpain Therapeutics Pty Ltd
Cancer Research UK
CdmoGen Co Ltd
Celiaz Co Ltd
Cellix Bio Pvt Ltd
Certa Therapeutics Pty Ltd
Character Biosciences Inc
Chong Kun Dang Pharmaceutical Corp.
Cloudbreak Therapeutics LLC
Connexin Therapeutics Inc
D-Sight SL
D. Western Therapeutics Institute Inc
Diorasis Therapeutics
Dompe Farmaceutici SpA
Eli Lilly and Co
Emmecell LLC
Evotec SE
Eye Bio Korea Co Ltd
Eyevensys SAS
FasT Biopharma Ltd
Future Medicine Co Ltd
Galimedix Therapeutics Ltd
Glaukos Corp
Guangzhou Cellprotek Pharmaceutical Co Ltd
Guangzhou Magpie Pharmaceutical Co Ltd
Guangzhou Runer Ophthalmic Biotechnology Co Ltd
Gurus BioPharm Inc
Handok Inc
Hefei Starry Gene Biotechnology Co Ltd
HitGen Inc
HK inno.N Corp
Human Cell Corp
Huons Global Co Ltd
Icahn School of Medicine at Mount Sinai
ID Pharma Co Ltd
Ildong Pharmaceutical Co Ltd
Incannex Healthcare Ltd
Indiana University-Purdue University Indianapolis
Industrial Technology Research Institute
Ingenia Therapeutics Inc
InMed Pharmaceuticals Inc
Isarna Therapeutics GmbH
IVIEW Therapeutics Inc
jCyte Inc
Jenivision Inc
Kodiak Sciences Inc
Korea Research Institute of Chemical Technology
Kowa Co Ltd
KP Biosciences Inc
Kukje Pharmaceutical Industry Co Ltd
KYORIN Pharmaceutical Co Ltd
Kyoto University
Laboratoires Thea SA
Laboratorios Salvat SA
Laboratorios Sophia SA de CV
LayerBio Inc
Lee's Pharmaceutical Holdings Ltd
Life Biosciences Inc.
Macquarie University
Matrix Biomed Inc
Medical University of South Carolina
MediPrint Ophthalmics Inc
MeiraGTx Holdings Plc
MimeTech Srl
Mitotech SA
MT-act
MyX Therapeutics Inc
NeurAegis Inc
Neuraly Inc
Neurizon Pharma GBR
Neurophoenix
Neuroptika Inc
NeuroScientific Biopharmaceuticals Ltd
Neurotech Pharmaceuticals Inc
Nexel Co Ltd
NicOx SA
NoNO Inc
Northwestern University
Novaliq GmbH
Novartis AG
Noveome Biotherapeutics Inc
Novoron Bioscience Inc
Ocular Therapeutix Inc
Oculis Holding AG
Oculo Therapy LLC
Oculogenex Inc
Ocumension Therapeutics Co Ltd
Ocuphire Pharma Inc
Oncolys BioPharma Inc
ONL Therapeutics Inc
Optus Pharmaceutical Co Ltd
Otsuka Pharmaceutical Co Ltd
Palatin Technologies Inc
Pasteur Institute
Perceive Biotherapeutics Inc
Perfuse Therapeutics Inc
pH Pharma Co Ltd
Pharmadrug Inc
Pharminogen Inc
Pinotbio Inc
PolyActiva Pty Ltd
Profarma
Q BioMed Inc
Qlaris Bio Inc
Quark Pharmaceuticals Inc
Qurgen Inc
Radikal Therapeutics Inc
Rebio Technologies Ltd
Rebus Holdings Inc
Regeneron Pharmaceuticals Inc
ReNetX Bio
Retinset SL
Ripple therapeutics Corp
Roca Therapeutics SAS
Santen Pharmaceutical Co Ltd
Senju Pharmaceutical Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
SIFI SpA
Skye Bioscience Inc
Sun Pharmaceutical Industries Ltd
Sustained Nano Systems LLC
Suzhou Ribo Life Sciences Co Ltd
Sylentis SAU
TaeJoon Pharmaceuticals Co Ltd
TALLC Inc
Tarsier Pharma Ltd
TearClear Corp
Teraclon IDF SL
Theratocular Biotek Co Ltd
TikoMed AB
Tisbury Pharmaceuticals Ltd
Toa Eiyo Ltd
Topadur Pharma AG
Turn Biotechnologies Inc
University Medical Center Mainz
University of Arizona
University of Birmingham Medical School
University of Bristol
University of California San Diego
University of Minnesota
University of North Carolina at Chapel Hill
University of Pennsylvania
University of Wisconsin Madison
ViSci Ltd
Visiox Pharma LLC
Visus Therapeutics Inc
Viva Vision Biotech
Whitecap Biosciences LLC
Wuhan Neurophth Biological Technology Ltd
Xilingyuan Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Glaucoma reports
Pharmaceuticals
New
Focal Segmental Glomerulosclerosis (FSGS): Market View, Current and Future Competitive…
$3,495 | July 2026
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Glaucoma – Drugs In Development, 2024 in real time.

  • Access a live Glaucoma – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more